LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors

Ana Aparicio, Brittany North, Lindsey Barske, Xuemei Wang, Valentina Bollati, Daniel Weisenberger, Christine Yoo, Nizar Tannir, Erin Horne, Susan Groshen, Peter Jones, Allen Yang, Jean Pierre Issa

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Multiple clinical trials are investigating the use of the DNA methylation inhibitors azacitidine and decitabine for the treatment of solid tumors. Clinical trials in hematological malignancies have shown that optimal activity does not occur at their maximum tolerated doses but selection of an optimal biological dose and schedule for use in solid tumor patients is hampered by the difficulty of obtaining tumor tissue to measure their activity. Here we investigate the feasibility of using plasma DNA to measure the demethylating activity of the DNA methylation inhibitors in patients with solid tumors. We compared four methods to measure LINE-1 and MAGE-A1 promoter methylation in T24 and HCT116 cancer cells treated with decitabine treatment and selected Pyrosequencing for its greater reproducibility and higher signal to noise ratio. We then obtained DNA from plasma, peripheral blood mononuclear cells, buccal mucosa cells and saliva from ten patients with metastatic solid tumors at two different time points, without any intervening treatment. DNA methylation measurements were not significantly different between time point 1 and time point 2 in patient samples. We conclude that measurement of LINE-1 methylation in DNA extracted from the plasma of patients with advanced solid tumors, using Pyrosequencing, is feasible and has low within patient variability. Ongoing studies will determine whether changes in LINE-1 methylation in plasma DNA occur as a result of treatment with DNA methylation inhibitors and parallel changes in tumor tissue DNA.

Original languageEnglish
Pages (from-to)176-184
Number of pages9
JournalEpigenetics
Volume4
Issue number3
DOIs
Publication statusPublished - Apr 1 2009

Fingerprint

DNA Methylation
Methylation
Biomarkers
DNA
decitabine
Neoplasms
Clinical Trials
HCT116 Cells
Azacitidine
Maximum Tolerated Dose
Mouth Mucosa
Signal-To-Noise Ratio
Hematologic Neoplasms
Therapeutics
Saliva
Blood Cells
Appointments and Schedules

Keywords

  • Biomarkers
  • Cancer
  • DNA methylation
  • LINE
  • MAGE-A1
  • Plasma DNA
  • Repetitive elements

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

Aparicio, A., North, B., Barske, L., Wang, X., Bollati, V., Weisenberger, D., ... Issa, J. P. (2009). LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics, 4(3), 176-184. https://doi.org/10.4161/epi.4.3.8694

LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. / Aparicio, Ana; North, Brittany; Barske, Lindsey; Wang, Xuemei; Bollati, Valentina; Weisenberger, Daniel; Yoo, Christine; Tannir, Nizar; Horne, Erin; Groshen, Susan; Jones, Peter; Yang, Allen; Issa, Jean Pierre.

In: Epigenetics, Vol. 4, No. 3, 01.04.2009, p. 176-184.

Research output: Contribution to journalArticle

Aparicio, A, North, B, Barske, L, Wang, X, Bollati, V, Weisenberger, D, Yoo, C, Tannir, N, Horne, E, Groshen, S, Jones, P, Yang, A & Issa, JP 2009, 'LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors', Epigenetics, vol. 4, no. 3, pp. 176-184. https://doi.org/10.4161/epi.4.3.8694
Aparicio, Ana ; North, Brittany ; Barske, Lindsey ; Wang, Xuemei ; Bollati, Valentina ; Weisenberger, Daniel ; Yoo, Christine ; Tannir, Nizar ; Horne, Erin ; Groshen, Susan ; Jones, Peter ; Yang, Allen ; Issa, Jean Pierre. / LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. In: Epigenetics. 2009 ; Vol. 4, No. 3. pp. 176-184.
@article{ce8f2f066e5b428da9e5a2adbfdf989a,
title = "LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors",
abstract = "Multiple clinical trials are investigating the use of the DNA methylation inhibitors azacitidine and decitabine for the treatment of solid tumors. Clinical trials in hematological malignancies have shown that optimal activity does not occur at their maximum tolerated doses but selection of an optimal biological dose and schedule for use in solid tumor patients is hampered by the difficulty of obtaining tumor tissue to measure their activity. Here we investigate the feasibility of using plasma DNA to measure the demethylating activity of the DNA methylation inhibitors in patients with solid tumors. We compared four methods to measure LINE-1 and MAGE-A1 promoter methylation in T24 and HCT116 cancer cells treated with decitabine treatment and selected Pyrosequencing for its greater reproducibility and higher signal to noise ratio. We then obtained DNA from plasma, peripheral blood mononuclear cells, buccal mucosa cells and saliva from ten patients with metastatic solid tumors at two different time points, without any intervening treatment. DNA methylation measurements were not significantly different between time point 1 and time point 2 in patient samples. We conclude that measurement of LINE-1 methylation in DNA extracted from the plasma of patients with advanced solid tumors, using Pyrosequencing, is feasible and has low within patient variability. Ongoing studies will determine whether changes in LINE-1 methylation in plasma DNA occur as a result of treatment with DNA methylation inhibitors and parallel changes in tumor tissue DNA.",
keywords = "Biomarkers, Cancer, DNA methylation, LINE, MAGE-A1, Plasma DNA, Repetitive elements",
author = "Ana Aparicio and Brittany North and Lindsey Barske and Xuemei Wang and Valentina Bollati and Daniel Weisenberger and Christine Yoo and Nizar Tannir and Erin Horne and Susan Groshen and Peter Jones and Allen Yang and Issa, {Jean Pierre}",
year = "2009",
month = "4",
day = "1",
doi = "10.4161/epi.4.3.8694",
language = "English",
volume = "4",
pages = "176--184",
journal = "Epigenetics",
issn = "1559-2294",
publisher = "Taylor and Francis Inc.",
number = "3",

}

TY - JOUR

T1 - LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors

AU - Aparicio, Ana

AU - North, Brittany

AU - Barske, Lindsey

AU - Wang, Xuemei

AU - Bollati, Valentina

AU - Weisenberger, Daniel

AU - Yoo, Christine

AU - Tannir, Nizar

AU - Horne, Erin

AU - Groshen, Susan

AU - Jones, Peter

AU - Yang, Allen

AU - Issa, Jean Pierre

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Multiple clinical trials are investigating the use of the DNA methylation inhibitors azacitidine and decitabine for the treatment of solid tumors. Clinical trials in hematological malignancies have shown that optimal activity does not occur at their maximum tolerated doses but selection of an optimal biological dose and schedule for use in solid tumor patients is hampered by the difficulty of obtaining tumor tissue to measure their activity. Here we investigate the feasibility of using plasma DNA to measure the demethylating activity of the DNA methylation inhibitors in patients with solid tumors. We compared four methods to measure LINE-1 and MAGE-A1 promoter methylation in T24 and HCT116 cancer cells treated with decitabine treatment and selected Pyrosequencing for its greater reproducibility and higher signal to noise ratio. We then obtained DNA from plasma, peripheral blood mononuclear cells, buccal mucosa cells and saliva from ten patients with metastatic solid tumors at two different time points, without any intervening treatment. DNA methylation measurements were not significantly different between time point 1 and time point 2 in patient samples. We conclude that measurement of LINE-1 methylation in DNA extracted from the plasma of patients with advanced solid tumors, using Pyrosequencing, is feasible and has low within patient variability. Ongoing studies will determine whether changes in LINE-1 methylation in plasma DNA occur as a result of treatment with DNA methylation inhibitors and parallel changes in tumor tissue DNA.

AB - Multiple clinical trials are investigating the use of the DNA methylation inhibitors azacitidine and decitabine for the treatment of solid tumors. Clinical trials in hematological malignancies have shown that optimal activity does not occur at their maximum tolerated doses but selection of an optimal biological dose and schedule for use in solid tumor patients is hampered by the difficulty of obtaining tumor tissue to measure their activity. Here we investigate the feasibility of using plasma DNA to measure the demethylating activity of the DNA methylation inhibitors in patients with solid tumors. We compared four methods to measure LINE-1 and MAGE-A1 promoter methylation in T24 and HCT116 cancer cells treated with decitabine treatment and selected Pyrosequencing for its greater reproducibility and higher signal to noise ratio. We then obtained DNA from plasma, peripheral blood mononuclear cells, buccal mucosa cells and saliva from ten patients with metastatic solid tumors at two different time points, without any intervening treatment. DNA methylation measurements were not significantly different between time point 1 and time point 2 in patient samples. We conclude that measurement of LINE-1 methylation in DNA extracted from the plasma of patients with advanced solid tumors, using Pyrosequencing, is feasible and has low within patient variability. Ongoing studies will determine whether changes in LINE-1 methylation in plasma DNA occur as a result of treatment with DNA methylation inhibitors and parallel changes in tumor tissue DNA.

KW - Biomarkers

KW - Cancer

KW - DNA methylation

KW - LINE

KW - MAGE-A1

KW - Plasma DNA

KW - Repetitive elements

UR - http://www.scopus.com/inward/record.url?scp=66449125866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66449125866&partnerID=8YFLogxK

U2 - 10.4161/epi.4.3.8694

DO - 10.4161/epi.4.3.8694

M3 - Article

C2 - 19421002

AN - SCOPUS:66449125866

VL - 4

SP - 176

EP - 184

JO - Epigenetics

JF - Epigenetics

SN - 1559-2294

IS - 3

ER -